Loading
Led KEYNOTE-052 and IMvigor210 cohort 1, establishing first-line immunotherapy for cisplatin-ineligible bladder cancer.
Arjun Balar led KEYNOTE-052 and the cisplatin-ineligible cohort of IMvigor210, the studies that gave pembrolizumab and atezolizumab their first-line approvals in urothelial cancer for patients who cannot receive cisplatin, and KEYNOTE-057 in BCG-unresponsive non-muscle-invasive disease. He continues to lead combination and bladder-preservation trials at NYU.
Shares PD-1, Bladder & urothelial cancer, Pembrolizumab, Immune checkpoint inhibitors and the tags urothelial, immunotherapy.
Shares Atezolizumab, PD-L1, Bladder & urothelial cancer, Immune checkpoint inhibitors and the tags urothelial, immunotherapy.
Shares PD-1, Bladder & urothelial cancer, Immune checkpoint inhibitors and the tags urothelial, immunotherapy.
Shares PD-L1, PD-1, Immune checkpoint inhibitors and the tag immunotherapy.
Shares PD-1, Pembrolizumab, Immune checkpoint inhibitors and the tag immunotherapy.
Shares PD-1, Bladder & urothelial cancer, Pembrolizumab, Immune checkpoint inhibitors and the tag urothelial.
Shares PD-L1, PD-1, Immune checkpoint inhibitors and the tag immunotherapy.
Shares Atezolizumab, PD-L1, PD-1, Pembrolizumab and the tag immunotherapy.